Destiny Pharma PLC Dr Jesús Gonz z appointed Chief Medical Officer (9296B)
September 26 2018 - 2:01AM
UK Regulatory
TIDMDEST
RNS Number : 9296B
Destiny Pharma PLC
26 September 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Destiny Pharma plc
("Destiny" or "the Company")
Destiny Pharma announces appointment of Chief Medical
Officer
Dr Jesús González brings extensive experience in the clinical
development of anti-infectives, as the Company prepares to initiate
a Phase 2b trial for lead asset
Brighton, United Kingdom - 26 September 2018 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs, which address the global
problem of antimicrobial resistance (AMR), today announces the
appointment of Jesús M González Moreno, M.D. as Chief Medical
Officer (CMO) of the Company, with immediate effect.
Dr González is an infectious disease expert with more than 11
years' experience of working within global pharmaceutical and
biotechnology companies to design, coordinate and execute clinical
development plans for anti-infective drug candidates. His
experience spans from early and late clinical development to
medical affairs and preparation for marketing authorisation
submissions. Dr González most recently served as Global Clinical
Development Director at TiGenix SAU in Spain, where he was
responsible for the overall development strategy for Cx611, a stem
cell treatment for sepsis secondary to community-acquired
pneumonia, including the design and implementation of its Phase
1b/2a clinical trial.
Prior to that Dr González worked at Basilea Pharmaceutcia in
Switzerland as Medical Science Liaison team leader, responsible for
the global medical plan for anti-infectives. Dr González also held
a number of medical director roles at AstraZeneca within their
Infection division, where he contributed to the development
strategy, was responsible for the coordination and implementation
of Phase 2-3 trials for novel antibiotics and collaborated in
regulatory fillings globally. Additionally, Dr González worked as
Regional Director of Medical Affairs in Antibiotics &
Antifungals for Merck&Co and MSD, responsible for the
development and implementation of regional medical and scientific
strategy for these anti-infectives in Europe, Middle East, Africa,
and Canada.
Dr González is a licensed physician with a medical doctor degree
from the Universidad Autónoma de Madrid, Spain. Dr González also
received a master's degree in Statistics and Study Design for
Research in the Health Sciences from the Universidad Autónoma de
Barcelona. Dr González completed his postdoctoral fellowship in
emerging and re-emerging infectious diseases at the Uniformed
Services University of the Health Sciences, Department of Defence,
Maryland, US.
Neil Clark, Chief Executive Officer of Destiny Pharma,
commented:
"I am delighted to welcome Dr González to the senior management
team as our new Chief Medical Officer. Jesús brings a wealth of
knowledge and experience in the clinical development of
anti-infective drugs, from early stage development through to
regulatory submission. Dr González' proven track record will be
invaluable to Destiny Pharma as we continue to progress the
development of our novel XF drugs to address antimicrobial
resistance and I look forward to working closely with him."
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMMGZLGKNGRZZ
(END) Dow Jones Newswires
September 26, 2018 02:01 ET (06:01 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024